Harvard Bioscience Faces Delisting Concerns
Ticker: HBIO · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1123494
| Field | Detail |
|---|---|
| Company | Harvard Bioscience Inc (HBIO) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, compliance
TL;DR
Harvard Bioscience might be delisted, check exchange status.
AI Summary
Harvard Bioscience, Inc. filed an 8-K on October 3, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective October 2, 2025. The company is based at 84 October Hill Road, Holliston, MA.
Why It Matters
This filing indicates potential issues with Harvard Bioscience's compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — Delisting or failure to meet listing standards poses a significant risk to the company's market presence and investor accessibility.
Key Players & Entities
- HARVARD BIOSCIENCE, INC. (company) — Registrant
- October 2, 2025 (date) — Date of earliest event reported
- October 3, 2025 (date) — Filing date
- 84 October Hill Road, Holliston, MA 01746 (address) — Principal Executive Offices
FAQ
What specific listing rule or standard has Harvard Bioscience failed to satisfy?
The filing states a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule or standard in this excerpt.
When did the potential delisting event occur?
The earliest event reported is October 2, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 84 October Hill Road, Holliston, MA 01746.
What is Harvard Bioscience's state of incorporation?
Harvard Bioscience, Inc. is incorporated in Delaware.
What is the SEC file number for Harvard Bioscience?
The SEC file number for Harvard Bioscience is 001-33957.
Filing Stats: 861 words · 3 min read · ~3 pages · Grade level 13.8 · Accepted 2025-10-03 08:01:27
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value HBIO The Nasdaq Stock Marke
- $1.00 — , which requires a minimum bid price of $1.00 per share (the "Minimum Bid Price Requi
Filing Documents
- f8k_100225.htm (8-K) — 22KB
- logo.jpg (GRAPHIC) — 11KB
- 0001171843-25-006260.txt ( ) — 212KB
- hbio-20251002_lab.xml (EX-101.LAB) — 33KB
- hbio-20251002_pre.xml (EX-101.PRE) — 22KB
- hbio-20251002.xsd (EX-101.SCH) — 3KB
- f8k_100225_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 2, 2025, Harvard Bioscience, Inc., (the "Company") received a notification letter from the Nasdaq Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had been granted an additional 180 days, or until March 30, 2026 (the "Second Compliance Period"), to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the "Minimum Bid Price Requirement"), based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period. In order to be eligible to receive the Second Compliance Period, the Company applied to have its common stock (the "Common Stock") transferred from the Nasdaq Global Market to the Nasdaq Capital Market. In connection with the grant of the Second Compliance Period, the application was approved and the Common Stock will move to the Nasdaq Capital Market effective at the opening of business on October 3, 2025. As previously disclosed by the Company in a Current Report on Form 8-K filed on April 10, 2025, the Company received a notification letter from the Staff notifying the Company that, because the closing bid price for the Common Stock listed on the Nasdaq Global Market had been below $1.00 for 30 consecutive business days, the Company no longer met the Minimum Bid Price Requirement. If at any time before March 30, 2026, the bid price of the Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff wil